An interventional study of Treatment with low-thermal argon plasma devitalization and Sham treatment in Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Intraepithelial Neoplasia Grade 2 and CIN2, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Uterine Cervical Dysplasia with a site in Germany — 3 open to participants now, 3 under way, none of them phase 3. Uterine Cervical Dysplasia · Germany.
Among the 26 studies in Uterine Cervical Dysplasia with a site in Germany, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is one of 17 with no phase, and was the 26th registered.
409 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.
Browse Uterine Cervical Dysplasia studies →3 of the 26 studies in Uterine Cervical Dysplasia with a site in Germany are open now. Recruiting first, the newest first:
Ruhr University of Bochum · Sites in Germany
Ages 18+ · Women only
Ruhr University of Bochum · Sites in Germany
Ages 18+ · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 3
First in 2005; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 264 is above the median of 167 across 285 interventional studies indexed under Uterine Cervical Dysplasia.
Median enrollment 201 across the 25 interventional studies, 323 across the 1 observational. Of the 23 that completed or were terminated, 5 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 26 have an industry lead sponsor. The 7 most frequent:
University Hospital Tuebingen is the lead sponsor of 491 studies on the registry; 109 are open to participants now.
University Hospital Tuebingen has 3 studies filed under Uterine Cervical Dysplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Uterine Cervical Dysplasia with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to show that treatment with LtAPD works better than a sham treatment or simply monitoring the condition closely without active treatment ("active surveillance"), in achieving complete healing of a tissue abnormality on the cervix called CIN 2, after 6 months. This will be confirmed by examining tissue samples under a microscope (histopathological examination).
Participation in the study lasts 6 months. Eligible participants are randomly assigned to one of two groups: participants receiving LtAPD treatment (treatment group) or participants receiving a sham procedure, in which LtAPD treatment is simulated but not actually applied (control group). All participants continue to be managed according to the current standard of care, active surveillance with regular monitoring, throughout the study. Participants remain blinded to their treatment assignment. The study includes four visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with low-thermal argon plasma devitalization
Device: Treatment with low-thermal argon plasma devitalization
Sham treatment
Device: Sham treatment
Single session of LtAPD treatment applied to the CIN2 lesion under colposcopic guidance; outpatient, no anesthesia required.
Single session of sham treatment (no argon gas delivery and plasma ignition; acoustic signal to maintain blinding) followed by active surveillance according to current clinical guidelines.
Histopathological remission of CIN 2
Percentage of patients with histopathologically confirmed remission of CIN 2 (absence of CIN 2 or higher grade lesion), assessed by cervical biopsy/histopathological evaluation
Time frame: at 6 months
HPV remission rate
Percentage of patients with HPV remission, assessed by validated HPV testing and p16 immunohistochemistry
Time frame: at 6 months
Cytological remission of CIN
Percentage of patients with cytological remission, assessed by Papanicolaou (PAP) smear according to the Bethesda classification system
Time frame: at 6 months
Quality of life, comfort/ discomfort of the treatment procedure and sexual activity
Change from baseline in quality of life and sexual health at baseline and 6 months, assessed by the Freiburg Index of Patient Satisfaction (FIPS) and the Sexual Activity Questionnaire (SAQ)
Time frame: at baseline, intervention, 6 months
Correlation of electrosurgical unit (ESU) and video data with CIN remission and applied argon plasma
assessed by correlation of ESU and video data with CIN remission and applied argon plasma
Time frame: at 6 months
Plan to share: No — There is not a plan to make IPD available.
Started Sep 2026 (actual). Primary completion is estimated for Mar 2029, 30 months after the start.
Of 78 non-industry interventional studies with no phase under Uterine Cervical Dysplasia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 30 months is above that.
Counting every sponsor, half of 82 studies reached it within 26 months; a quarter within 13 and three quarters within 54.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 1, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Tuebingen →